Taddese Desta, MD
Gastroenterology · San Diego, CANPI 1346326246
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 281 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 44.4% of the total.
Across 281 payments — averaging $19.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Gilead$449
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$431
- Takeda Pharmaceuticals U.S.A., Inc.$362
- Pfizer$257
- Johnson & Johnson$246
- plus $1K from 17 others
Across 509 payments — averaging $2736.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ironwood Pharmaceuticals, Inc$272K
- Pfizer$249K
- AbbVie$194K
- Regeneron$160K
- Genentech, Inc.$142K
- Braintree Laboratories, Inc.$125K
- plus $251K from 10 others
What the payments were for
- Food & beverage$5,38498%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 141 | $2,434 |
| Gilead | 25 | $449 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 23 | $431 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $362 |
| Pfizer | 12 | $257 |
| Johnson & Johnson | 11 | $246 |
| Intercept Pharmaceuticals, Inc. | 12 | $245 |
| Nestle Healthcare Nutrition Inc. | 9 | $171 |
| Madrigal Pharmaceuticals | 5 | $171 |
| Micro-tech Endoscopy USA, Inc. | 3 | $153 |
| Merck | 3 | $129 |
| Regeneron Healthcare Solutions, Inc. | 4 | $100 |
| Braintree Laboratories, Inc. | 5 | $91 |
| Shionogi Inc | 3 | $47 |
| Sanofi | 1 | $43 |
| Medtronic | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Redhill Biopharma Inc. | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| QOL Medical, LLC | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Ardelyx, Inc. | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
How this compares
$5,484 in reported general payments places this provider in the 70th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 96 | $64,478 |
| VemlidyTenofovir Alafenamide | 33 | $47,933 |
| ViberziEluxadoline | 19 | $29,612 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 68 | $4,262 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 92 | $1,399 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 76 | $1,025 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 58 | $935 |
| Pantoprazole Sodium | 103 | $700 |
| Entecavir | 12 | $299 |
| Famotidine | 29 | $240 |
| Omeprazole | 50 | $232 |
| Esomeprazole Magnesium | 13 | $219 |
| Metronidazole | 14 | $117 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Viberzi | $2,434 | $94,090115 claims |
| GileadVemlidy | $449 | $47,93333 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,885 gastroenterology providers in California.
Other gastroenterology in San Diego
- William SandbornSan Diego$340K
- David KunkelSan Diego$287K
- Naveen GaraSan Diego$178K
- Bennett RothLos Angeles$2.8M
- Douglas NguyenMission Viejo$2M
- Sammy SaabLos Angeles$1.9M
- Kenneth ChangNewport Beach$1.3M
- Joo HwangStanford$1M
- Drew SchembreWalnut Creek$659K
- Quan Nhula Jolla$641K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.